StockData
Phibro Animal Health Corp logo

Phibro Animal Health Corp (PAHC) stock

PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$34.92−0.10 (-0.29%)

Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%

Phibro Animal Health r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $24.55M, up 3.5% from the year before. Over ten years it grew 8.3% a year on average. The highest annual figure on record is $29.19M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$24.55M+3.5%
FY2025Jun 30, 2025$23.73M-18.7%
FY2024Jun 30, 2024$29.19M+19.7%
FY2023Jun 30, 2023$24.40M+17.1%
FY2022Jun 30, 2022$20.83M+17.3%
FY2021Jun 30, 2021$17.76M+29.3%
FY2020Jun 30, 2020$13.74M+13.6%
FY2019Jun 30, 2019$12.09M+21.0%
FY2018Jun 30, 2018$10.00M+5.9%
FY2017Jun 30, 2017$9.44M-14.4%
FY2016Jun 30, 2016$11.03M+16.0%
FY2015Jun 30, 2015$9.51M+15.8%
FY2014Jun 30, 2014$8.21M+23.7%
FY2013Jun 30, 2013$6.64M-7.7%
FY2012Jun 30, 2012$7.19M–

More Phibro Animal Health figures

See a number that looks wrong?